Pepto Bismol May Not Prevent Traveler’s Diarrhea, New Study Finds

Medically reviewed by Drugs.com.

By I. Edwards HealthDay Reporter

WEDNESDAY, June 4, 2025 — Pepto Bismol is a go-to stomach remedy, but a new study suggests it might not help prevent diarrhea during international travel.

The study, led by the U.S. Centers for Disease Control and Prevention (CDC), found that people who took bismuth subsalicylate — the active ingredient in Pepto Bismol — did not have fewer episodes of diarrhea or loose stools than those who took a placebo, CBS News reported.

There was "no significant difference,” the researchers wrote May 29 in the Journal of Travel Medicine.

Pepto Bismol has been approved by the U.S. Food and Drug Administration (FDA) since 1939 to treat diarrhea, indigestion, heartburn, nausea and upset stomach. But many travelers take it off-label to try to prevent diarrhea during trips.

The study followed 270 adults who were planning to travel to parts of Southeast Asia, South Central Asia, North Africa or sub-Saharan Africa for one to three weeks.

The median age of the participants was 32 (meaning half were older, half younger). They were recruited from clinics in New York and Massachusetts.

One group took four tablets of bismuth subsalicylate twice a day while traveling. The other group took a placebo. Researchers collected data through questionnaires before, during and after the trip.

Even though the study didn’t reach its target number of participants, the findings still provide the first new data since the 1980s on preventive use of bismuth subsalicylate, the authors said.

The study suggests health care providers may want to rethink recommending Pepto Bismol for diarrhea prevention in travelers. Still, more research is needed.

"A larger study might show benefit, although the benefit may be small given the results of this study," said the reseachers, who were led by Dr. Kristina Angelo of the CDC's Division of Foodborne, Waterborne and Environmental Diseases.

The medication used in the trial was provided by Procter & Gamble, maker of Pepto Bismol.

However, the company did not take part in any part of the study, CBS News said.

Sources

  • CBS News, June 3, 2025
  • Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords